Notícias

Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.

Bristol-Myers Squibb Company will release earnings for its second quarter before the opening bell on Thursday, July 30. Analysts expect the company to report quarterly earnings of $1.60 per share, up from $1.46 per share in the year-ago period. The...

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

Bristol-Myers Squibb stock has delivered a 42.2% return over the past year, while the current checks suggest the shares are not a straightforward bargain or clear premium, with the Discounted Cash Flow (DCF) estimate pointing to meaningful upside against a more balanced overall valuation score. The 42.2% one year return signals that a lot more optimism is now reflected in Bristol-Myers Squibb's share price than a year ago. Expanded use of Nvidia AI systems and a new San Diego R&D hub can...

Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for.

Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

In recent days, Bristol Myers Squibb has been in focus as analysts updated earnings forecasts and a biotech partner sought approval for its first commercial product to be used alongside BMS’s cancer drug Opdivo. At the same time, commentators have highlighted Bristol Myers Squibb’s role as a dividend-oriented value name with a pipeline viewed as important for offsetting future patent expirations and evolving product sales trends. Building on this, we’ll explore how higher earnings...

Rather than going head-to-head with approved CAR-T cell therapies, biotechs like Caribou Biosciences are positioning their drugs to fill unique market gaps.

Today Federal Reserve meeting: Fed Chairman Kevin Warsh will hold a press conference at 2:30 p.m. ET, following the FOMC interest-rate decision at 2 p.m. Earnings (a.m): Procter & Gamble, Humana, L3Harris, Biogen, General Dynamics, Teva Pharmaceuticals, Airbus Earnings (p.

The biotech is seeking approval for its first commercial product in combination with Bristol Myers Squibb’s Opdivo.

Bristol Myers keeps making moves to establish a strong foundation for the future.

Replimune (NASDAQ: REPL) shares fell nearly 31% on Tuesday after US Food and Drug Administration (FDA) staff reviewers raised concerns over the effectiveness of the company’s lead cancer therapy, RP1, ahead of a key advisory committee meeting. The decline followed the release of FDA briefing...

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.

Today Earnings (a.m.): Coca-Cola, UPS, Boeing, Sherwin-Williams, Hilton, Centene, PayPal, S&P Global Earnings (p.m.): Visa, Ford Motor, Mondelez International, Waste Management, PPG Industries, Bloom Energy, Avis Budget, Seagate Technology Economic data: Consumer confidence index, Johnson Redbook retail sales index, U.

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.

Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.

IMCR's Kimmtrak sales climbed 29% in 2025 on wider adoption, with pivotal 2026 trial results set to test its next expansion opportunity.

Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.

In July 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 28-8 pharmDx assay as a companion diagnostic to identify patients with several gastric and esophageal cancers who may be eligible for treatment with Bristol Myers Squibb’s OPDIVO and OPDIVO QVANTIG, for use exclusively on the Agilent Autostainer Link 48 platform. This approval deepens Agilent’s role in immuno-oncology testing by tying its assay directly to widely used PD-1 therapies in...

Sometimes you need to look beyond the numbers to get the full story.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.